Compare · ARPO vs TRIL
ARPO vs TRIL
Side-by-side comparison of Aerpio Pharmaceuticals, Inc. (ARPO) and Trillium Therapeutics Inc. (TRIL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARPO and TRIL operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- TRIL is the larger of the two at $1.94B, about 4.6x ARPO ($425.1M).
- TRIL has more recent analyst coverage (5 ratings vs 1 for ARPO).
- Company
- Aerpio Pharmaceuticals, Inc.
- Trillium Therapeutics Inc.
- Price
- $2.19-1.57%
- $19.30-3.45%
- Market cap
- $425.1M
- $1.94B
- 1M return
- -
- -3.79%
- 1Y return
- -
- -5.02%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 1
- 5
Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
Trillium Therapeutics Inc.
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Latest ARPO
- SEC Form EFFECT filed by Aerpio Pharmaceuticals, Inc.
- SEC Form S-8 filed by Aerpio Pharmaceuticals, Inc.
- SEC Form S-3 filed by Aerpio Pharmaceuticals, Inc.
- Aerpio Pharmaceuticals, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)
- SEC Form 4 filed by Delaney Brendan
- SEC Form 3 filed by new insider Delaney Brendan
- Aerpio Pharmaceuticals, Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Aerpio Pharmaceuticals, Inc. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Desai Neil
- SEC Form 4 filed by Reeve Emma
Latest TRIL
- Defiance ETFs Announces Closure of Select Funds
- Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets
- Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
- 10 Psychedelics CEOs To Pay Attention To In 2022
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
- SEC Form 15-12B filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company
- SEC Form 4 filed by Pucci Paolo